6,678 trials
Type 2 Diabetes Mellitus
Primary: The Primary Endpoint Was the Change in FMD at the End of the Study Compared to Baseline Measurements in Subjects Treated With Exenatide Compared to Subjects Treated With…
Vestibular
Primary: Percent Change in Roll Tilt Perception After Exposure to Hypogravity — 27.0 percentage change
Influenza
Primary: Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, and Swelling) and Systemic Reactions (Fever, Headache, Malaise, Myalgia): Group 1 (3…
Acne Vulgaris
Primary: Mean Percent Change in Inflammatory, Non Inflammatory, and Total Lesion Counts From Baseline to Week 8 — -62.1; -49.8; -56.9 Percent change
Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression — 10.79; 15.30; 12.75 units on a scale
Type 1 Diabetes
Primary: Assessment of Changes in Glycemic Control by HbA1c. — 0.3; 0.2 percentage of HbA1c
Hypertension
Primary: Change in Mean Arterial Pressure — 110; 105; 100 mmHg
Asthma
Primary: Time-to-First Serious Asthma Outcomes (SAO): Number of First SAO in the MF/F vs MF Arms — 39; 32 Serious asthma outcomes — p=0.411
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Rating Scale — 18.9; 7.5 units on a scale
Asthma
Primary: Number of Participants in Each Arm With a Need for an Increase in Study Medication — 29; 29 Participants
Glaucoma
Primary: Least Squares Mean Change From Baseline in 24-hr Intraocular Pressure (IOP) at Week 4 — -3.09; -0.60 mmHg
HIV-1 Infection
Primary: Actual Glomerular Filtration Rate (aGFR) Using Iohexol Plasma Clearance (CLiohexol) at Week 24 — 103.6; 104.9; 111.1; 101.0 mL/min
Study is Open to Seniors Age 50 or Older
Primary: Knowledge and Awareness of Pneumococcal Disease — 13.90; 20.41; 21.43 scores on a scale
Muscle Relaxants
Primary: Fade on Train of Four Stimulation — 0.85; 0.64; 0.66; 0.68 Ratio
Adenine Phosphoribosyltransferase Deficiency
Primary: Urinary 2,8-dihydroxyadenine Excretion — 116; 45; 13 mg/24-h — p=<.05